Fresenius Medical Care Confirms Positive Outlook for 2010

Shareholders Approve 13th Consecutive Annual Dividend Increase

Bad Homburg, (PresseBox) - Fresenius Medical Care's Chief Executive Officer, Dr. Ben Lipps, continues to see attractive growth opportunities, confirming the company's positive outlook for the 2010 financial year at the annual general meeting in Frankfurt today. Lipps: "The 2009 fiscal year was another very successful one for Fresenius Medical Care. Once again, we were able to demonstrate that Fresenius Medical Care's business model is robust and sustainable. We had a very good start into 2010. We are clearly on track to meet our targets for the full year and achieve another record year." For 2010, Fresenius Medical Care expects more than $12 billion in revenue and net income1 between $950 million and $980 million.

Lipps also expects continued sustainable growth driven by an annual 5% to 6% increase in patients requiring dialysis treatment worldwide. Furthermore, Fresenius Medical Care will pursue strategic opportunities to consolidate its leading market positions. Key drivers of these opportunities include: increasing market share through a superior product portfolio, a strong commitment to quality, expanding the clinic network, a focus on integrated care and rolling out additional dialysis services.

Lipps also pointed out a significant increase in its number of employees. The addition of 3,322 people, an increase of 5.0% to a total of approximately 68,000 employees worldwide, was attributed primarily to strong organic growth of the dialysis care business in every region. Selected acquisitions also contributed to this growth. The number of employees is expected to rise again in 2010.

During the annual general meeting, the shareholders approved the 13th consecutive dividend increase with a large majority of 99.02%. The dividend will increase to €0.61 from €0.58 per ordinary share and to €0.63 from €0.60 per preference share.

With a further majority of 96.80%, shareholders also approved cancellation of the existing authorized capital along with the creation of new authorized capitals identical to those expiring in August 2010 and totaling up to €35 million and €25 million, respectively.

In addition, shareholders approved the actions taken and decisions made by the supervisory board and the management board with a majority of more than 99%.

At the annual general meeting, 74.36% of the subscribed capital was represented. Only ordinaryshare holders were entitled to vote.

This release contains forwardlooking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forwardlooking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forwardlooking statements in this release.

Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,890,000 individuals worldwide. Through its network of 2,580 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 198,774 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.